Ketipinor

Quetiapine, the active ingredient in Ketipinor, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia, bipolar disorder (both manic and depressive phases), and as an adjunct in major depressive disorder in adult patients.

GNH USA supplies Ketipinor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Ketipinor (quetiapine) is used in psychiatric disorders that involve dysregulation of dopamine and serotonin pathways. - Schizophrenia: reduces positive and negative symptoms and improves overall functioning. - Bipolar disorder (manic episodes): stabilizes mood and decreases mania severity. - Bipolar disorder (depressive episodes): alleviates depressive symptoms. - Major depressive disorder (adjunct): enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling of sleepiness or fatigue. - Dry mouth: reduced salivation leading to discomfort. - Constipation: infrequent bowel movements. - Weight gain: increase in body weight over time. - Orthostatic hypotension: dizziness upon standing. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Agranulocytosis: severe reduction in white blood cells. - Suicidal thoughts: emergence or worsening of suicidal ide